Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity

• Published in: Diagnostics (Basel) Vol. 11; no. 3; p. 526
• Main Authors: Silva Raju, Janisha, Abd Aziz, Nor Haslinda, Atallah, Ghofraan Abdulsalam, Teik, Chew Kah, Shafiee, Mohamad Nasir, Mohd Saleh, Muhammad Fakhri, Jeganathan, Ravichandran, Md Zin, Reena Rahayu, Kampan, Nirmala Chandralega
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 16.03.2021; MDPI
• Subjects: Antibodies; Cancer therapies; Chemotherapy; Disease; Drug dosages; high-grade serous ovarian cancer (HGSC); Immunotherapy; Kinases; Medical prognosis; Ovarian cancer; platinum resistant (PR); platinum sensitive (PS); progression free survival (PFS); Protein expression; Proteins; signal transducer and activator of transcription 3 (STAT3); Surgery; tumour necrosis factor receptor 2 (TNFR2); Denmark; United States > US; Malaysia; platinum sensitive (PS); platinum resistant (PR); high-grade serous ovarian cancer (HGSC); progression free survival (PFS); signal transducer and activator of transcription 3 (STAT3); tumour necrosis factor receptor 2 (TNFR2)
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics11030526

This study's goal was to determine the protein expression level of tumour necrosis factor receptor 2 (TNFR2) and signal transducer and activator of transcription 3 (STAT3) in high-grade serous ovarian cancer (HGSC) tissues in relation to the platinum-based chemotherapy response and the prognosis outcome. A total of 25 HGSC patients underwent primary surgical debulking followed by first-line adjuvant platinum-based chemotherapy. Tissue microarray (TMA) slides were constructed utilising archived formalin fixed paraffin embedded (FFPE). The protein expression of TNFR2 and STAT3 were analysed using immunohistochemistry (IHC) staining and subsequently were correlated to the clinicopathological characteristics, platinum sensitivity as well as the duration of progression-free survival. About 14 out of 25 patients (56.0%) were platinum-sensitive. The progression free survival was significantly longer in the platinum-sensitive (PS) group when compared to those with the platinum-resistant group (PR), = 0.0001. Among patients with TNFR2 strong expression on ovarian tissue, there was a significantly longer progression-free survival interval of 540 days in the PS group compared to PR, = 0.0001. Patients with STAT3 expression also showed significantly better progression-free survival of 660 days in the PS group when compared to the PR group, = 0.0001. In conclusion, patients with strong TNFR2 and STAT3 expression in the ovarian tissue had significantly longer progression-free survival interval in the PS group. Nevertheless, further research with a larger number of tissues may be required to demonstrate further significant differences.